Proactive Investors - Run By Investors For Investors

ValiRx agrees break fee as it terminates financing agreement

ValiRx will pay a break fee of £212,500 to European High Growth Opportunities SF after the pair agreed to terminate the financing deal
handshake
The two parties entered into the subscription agreement at the end of April

Drug developer ValiRx Plc (LON:VAL) has agreed to terminate a financing agreement with European High Growth Opportunities Securitisation Fund.

As part of the deal, ValiRx is paying the investor a £212,500 break fee; slightly higher than the £150,000 bosses had previously expected.

The fee will be paid in shares issued at the lowest closing price during the five days prior to the payment. ValiRx said this would protect its current cash position.

READ: ValiRx raises funds to meet immediate working capital needs

The company reminded investors that a £400,000 tax credit is due next month, while it has also raked in another £150,000 from the sale of an unlisted security.

A recent £300,000 share placing has also helped to top up the coffers.

“As previously announced, the company's working capital position is dependent on new funds being made available to it and it continues to manage its working capital position carefully.”

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares.

ValiRx shares were down 1.7% in late-afternoon trading on Tuesday.

View full VAL profile View Profile

ValiRx PLC Timeline

Big Picture
May 02 2019

Related Articles

1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use